LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

Home・Elenco Azioni・Erasca Inc

Erasca Inc

Aperta

10.38 2.77

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.06

Massimo

10.67

Metriche Chiave
By Trading Economics
Entrata	1.5M -29M
Dipendenti	103
EBITDA	-2M -32M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+99.6% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.7B 3.2B
Apertura precedente	7.61
Chiusura precedente	10.38

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

1.39 / 1.44 Supporto e resistenza

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 mag 2026, 23:47 UTC

Discorsi di Mercato

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mag 2026, 23:38 UTC

Discorsi di Mercato

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mag 2026, 23:14 UTC

Discorsi di Mercato

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mag 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mag 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mag 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mag 2026, 10:21 UTC

Utili

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mag 2026, 06:05 UTC

Utili

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mag 2026, 23:55 UTC

Utili

Review & Preview: Still Going Strong -- Barrons.com

8 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 20:49 UTC

Utili

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mag 2026, 20:25 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Net $115M

8 mag 2026, 19:20 UTC

Discorsi di Mercato

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mag 2026, 19:18 UTC

Utili

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mag 2026, 19:16 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:08 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:05 UTC

Utili

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mag 2026, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mag 2026, 18:51 UTC

Utili

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mag 2026, 18:49 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 18:41 UTC

Utili

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mag 2026, 17:14 UTC

Utili

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mag 2026, 17:04 UTC

Discorsi di Mercato

Zcash Caps Off Parabolic Week -- Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

99.6% in crescita

Previsioni per 12 mesi

Media 20.2 USD 99.6%

Alto 30 USD

Basso 9 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.39 / 1.44Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.